NEWS 

  • ​JUNAXO PRESENTS AT THE INTERNATIONAL CONGRESS OF PARKINSON'S DISEASE AND MOVEMENT DISORDERS, OCT 2018 [MORE]​​


  • JUNAXO PUBLISHES KEY PRECLINICAL DATA ON JNX3001 [MORE]


Junaxo is a drug development company specializing in repurposing compounds for the treatment of Parkinson’s disease and amyotrophic lateral sclerosis.


We are currently seeking investment to advance our clinical assets through proof-of-principle Phase II clinical studies.


Our Business Plan and Pitch Deck can be accessed here. Contact us at info@junaxo.com or call on +1 647-961-2644 for more information.